JP2011219478A5 - - Google Patents

Download PDF

Info

Publication number
JP2011219478A5
JP2011219478A5 JP2011104172A JP2011104172A JP2011219478A5 JP 2011219478 A5 JP2011219478 A5 JP 2011219478A5 JP 2011104172 A JP2011104172 A JP 2011104172A JP 2011104172 A JP2011104172 A JP 2011104172A JP 2011219478 A5 JP2011219478 A5 JP 2011219478A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011104172A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011219478A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2011104172A priority Critical patent/JP2011219478A/ja
Priority claimed from JP2011104172A external-priority patent/JP2011219478A/ja
Publication of JP2011219478A publication Critical patent/JP2011219478A/ja
Publication of JP2011219478A5 publication Critical patent/JP2011219478A5/ja
Pending legal-status Critical Current

Links

JP2011104172A 2009-03-19 2011-05-09 関節リウマチ治療剤 Pending JP2011219478A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011104172A JP2011219478A (ja) 2009-03-19 2011-05-09 関節リウマチ治療剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2009067358 2009-03-19
JP2009067358 2009-03-19
JP2011104172A JP2011219478A (ja) 2009-03-19 2011-05-09 関節リウマチ治療剤

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2010511837A Division JP4809930B2 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤

Publications (2)

Publication Number Publication Date
JP2011219478A JP2011219478A (ja) 2011-11-04
JP2011219478A5 true JP2011219478A5 (enExample) 2013-05-02

Family

ID=42739764

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010511837A Active JP4809930B2 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤
JP2011104172A Pending JP2011219478A (ja) 2009-03-19 2011-05-09 関節リウマチ治療剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2010511837A Active JP4809930B2 (ja) 2009-03-19 2010-03-19 関節リウマチ治療剤

Country Status (5)

Country Link
JP (2) JP4809930B2 (enExample)
KR (1) KR101314880B1 (enExample)
RU (1) RU2524152C2 (enExample)
TW (1) TWI457134B (enExample)
WO (1) WO2010107108A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10515A (enExample) 2006-03-31 2015-08-21 Chugai Pharmaceutical Co Ltd
KR101508019B1 (ko) 2007-01-23 2015-04-06 고쿠리츠 다이가쿠 호우징 신슈 다이가쿠 만성 거부반응 억제제
US10717781B2 (en) 2008-06-05 2020-07-21 National Cancer Center Neuroinvasion inhibitor
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP4115906A1 (en) 2010-05-28 2023-01-11 Chugai Seiyaku Kabushiki Kaisha Antitumor t cell response enhancer
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
EP3263132B1 (en) 2015-02-27 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Composition for treating il-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
TWI822728B (zh) 2018-01-31 2023-11-21 加藤元一 含有il-6抑制劑的哮喘治療劑
MX2021011464A (es) 2019-03-29 2021-10-22 Chugai Pharmaceutical Co Ltd Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).
MX2021012163A (es) 2019-04-17 2022-01-31 Univ Hiroshima Agente terapeutico para cancer urologico que se caracteriza por ser administrado con un inhibidor de il-6 y un inhibidor de ccr2 en combinacion.
CN115697404A (zh) 2020-05-29 2023-02-03 中外制药株式会社 含有抗体的制剂
EP4306127A4 (en) 2021-03-12 2025-04-09 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for the treatment or prevention of myasthenia gravis
WO2025198912A1 (en) 2024-03-21 2025-09-25 Hoffmann-La Roche Inc. Methods of treating myasthenia gravis

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012503A1 (en) * 1994-10-21 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Remedy for diseases caused by il-6 production
MX2007007935A (es) * 2004-12-28 2007-12-06 Innate Pharma Sa Anticuerpos monoclonales contra nkg2a.
AU2007285695B2 (en) * 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2009010539A2 (en) * 2007-07-19 2009-01-22 Ablynx. N.V. Receptor for interleukin-6 (il-6) from macaca fascicularis
DK3059246T3 (en) * 2007-09-26 2018-10-01 Chugai Pharmaceutical Co Ltd Modified constant region of an antibody
WO2009041621A1 (ja) * 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗il-6レセプター抗体
TWI700293B (zh) * 2008-04-11 2020-08-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗體
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules

Similar Documents

Publication Publication Date Title
JP2011219478A5 (enExample)
JP2012136541A5 (enExample)
JP2013517277A5 (enExample)
RU2011142183A (ru) Средство для лечения ревматоидного артрита
JP2012507294A5 (enExample)
JP2014205674A5 (enExample)
JP2013539454A5 (enExample)
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
WO2012006596A3 (en) Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
HRP20211343T1 (hr) Protutijela protiv dkk-1
CA2813849C (en) Secukinumab for use in the treatment of ankylosing spondylitis
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
JP2008538564A5 (enExample)
JP2015522252A5 (enExample)
HRP20161740T1 (hr) Ljudske molekule za vezanje koje su sposobne neutralizirati viruse influence a filogenetske skupine 1 i filogenetske skupine 2, te viruse influence b
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
RU2571204C3 (ru) Специфические связывающие агенты против в7-н1
JP2015514110A5 (enExample)
JP2018536393A5 (enExample)
JP2019500327A5 (enExample)
JP2011528902A5 (enExample)
JP2007051159A5 (enExample)
UA118441C2 (uk) Антитіло, що розпізнає альфа-синуклеїн
IN2012DN01328A (enExample)
JP2012526542A5 (enExample)